Company Overview and News
KUALA LUMPUR (Sept 13): AllianceDBS Research said Pasukhas Group Bhd (Pasukgb) had on Sept 13 settled at the day’s high of 11.5 sen (up 0.5 sen or 4.54%).
KUALA LUMPUR (Sept 13): Pasukhas Group Bhd rose 4.54% this morning after it secured a contract to sell a vessel of steam coal in South Kalimantan, Indonesia for US$4.93 million (RM20.44 million).
KUALA LUMPUR: Sapura Energy Bhd , Unisem (M) Bhd , Sunway Bhd , MY E.G. Services Bhd (MyEG), Pasukhas Group Bhd and Magni-Tech Industries Bhd are among the stocks to watch, according to JF Apex Research.
KUALA LUMPUR (Sept 12): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (Sept 13) may include the following: FGV Holdings Bhd, Sapura Energy Bhd, Unisem (M) Bhd, Sunway Bhd, MY E.G. Services Bhd, Pasukhas Group Bhd, Vertice Bhd, Land & General Bhd, Only World Group Holdings Bhd, MMAG Holdings Bhd and Magni-Tech Industries Bhd.
0177 5260 7087
KUALA LUMPUR: Construction company Pasukhas Group Bhd said its new venture into coal trading will soon become a major revenue stream for the financial year ending Dec 31, 2018 (FY18), contributing revenue of RM150 million in FY18.
KUALA LUMPUR (Aug 7): The FBM KLCI is seen trending sideways today with immediate support at 1,764, despite the firmer overnight close at most global markets, as buying support at the local bourse is likely to be lukewarm.
0177 5106 5260 7168 1481 9466
KUALA LUMPUR (Aug 6): Based on corporate announcements and news flow today, stocks in focus for Tuesday (Aug 7) may include the following: Sime Darby Plantation Bhd, PRG Holdings Bhd, Pasukhas Group Bhd, KKB Engineering Bhd, SKH Consortium Bhd, Axis Real Estate Investment Trust, Only World Group Holdings Bhd, MCT Bhd and Advance Synergy Bhd.
0177 5106 5260 7168 BSMAF 1481 9466 1818
KUALA LUMPUR (Aug 6): Pasukhas Group Bhd targets to comply with the Bumiputra Equity Requirements by year end.
KUALA LUMPUR: JF Apex Research expects Crest Builder Holdings Bhd , Pasukhas Group Bhd , Tien Wah Press Holdings Bhd , PUC Bhd and Comintel Corp Bhd to be among the stocks to watch today.
0177 8591 7374
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...